Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea

Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective.

Read the whole article on Physorg

More from Physorg